<?xml version="1.0" encoding="UTF-8"?>
<p>Concerning immunoglobulin therapy in COVID-19, 2 studies were identified (Table 
 <xref rid="T2" ref-type="table">2</xref>    , lower panels). The first one (NCT04261426) focuses on early administration of the immunoglobulin in severe cases, adopting an eligibility interval between the onset of symptoms and randomization that should not surpass 7 days. The second (NCT04261426) is a small exploratory study on 10 patients with the aim to evaluate this experimental treatment in severe COVID-19 pneumonia cases in China.
</p>
